Compare Recursion Pharmaceuticals Inc (RXRX) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Wix.Com Ltd — how do they compare? Recursion Pharmaceuticals Inc trades at $3.34 (market cap $1.78B), while Wix.Com Ltd trades at $66.7 (market cap $2.61B). The key difference: Wix.Com Ltd is the larger of the two by market cap. Which is the better fit depends on your goals.
| RXRX | WIX | |
|---|---|---|
Market Cap | $1.78B | $2.61B |
Sector | Health | Technology |
52-Week High | $6.79 | $184.24 |
52-Week Low | $2.84 | $40.43 |
Enterprise Value | $1.30B | $3.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Wix trades at $60.20, down 1.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $79.75 suggesting significant upside. Revenue grew to $1.99 billion in 2025, though net income margin remains negative at -8.19%. Recent earnings show three beats and one miss in the last four quarters, with a notable 27% price drop following the Q1 2026 miss.
The outlook is mixed: strong revenue growth and analyst optimism contrast with profitability challenges and a securities class action lawsuit alleging misleading statements. The stock offers potential for appreciation if execution improves, but faces near-term legal and operational risks that could pressure the share price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
